Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on small-molecule therapies for muscle disorders. The pipeline is anchored by three programs spanning three large therapeutic categories: sevasemten (lead asset, oral myosin inhibitor) in Phase 2 for Duchenne and Becker muscular dystrophy; EDG-7500 (Phase 1) for hypertrophic cardiomyopathy (HCM) as a differentiated alternative to Bristol-Myers Camzyos (mavacamten); and EDG-15400 (Phase 1) for heart failure with preserved ejection fraction (HFpEF) — a massive USD 20+ bn addressable market with no targeted therapies currently approved. FY2025 revenue zero (pre-commercial), operating cash burn of approximately USD 90 M, current ratio 22.6x reflects approximately USD 400 M cash and equivalents at end-2025 plus 2025 secondary offering. Runway through 2027-2028 without additional capital.

The 2026 strategic story has three threads. First, sevasemten Becker MD pivotal readout: LYNX (Becker) Phase 2 read out positive in 2024 with significant reduction in muscle damage biomarkers (creatine kinase, troponin) plus functional improvement on the North Star Ambulatory Assessment. The Phase 3 GRAND-DM pivotal trial initiated H2/2025 with primary endpoint readout expected H2/2027. Becker MD is a 15,000-patient US prevalence orphan indication with no approved therapy. Second, sevasemten Duchenne MD expansion: ARCH (Duchenne) Phase 2 showed clinical benefit including improvements in lung function and reduced muscle damage. Combined Becker + Duchenne addressable population is approximately 30,000 US patients, USD 2-3 bn peak sales potential at orphan pricing. Third, the cardiac portfolio: EDG-7500 enters Phase 2 in 2026 for HCM, with mechanism differentiated from Camzyos (cardiac TIE-2 versus cardiac-myosin) potentially offering broader patient applicability and better tolerability profile. EDG-15400 HFpEF Phase 2 starts 2026 — the highest-risk-highest-reward asset in the pipeline.

The 2026 question is whether sevasemten Phase 3 GRAND-DM trial maintains the Phase 2 efficacy signal, whether EDG-7500 Phase 1 safety data supports Phase 2 in HCM in mid-2026, and whether the platform's Phase 1 HFpEF data validates the broader muscle-disorder thesis.

Top holders Q1/2026: Vanguard 8.0%, BlackRock 6.6%, ARK Investment Management (Cathie Wood) approximately 5.8% (sustained position since 2024 accumulation), Baker Bros Advisors 4.4%, RA Capital Management 3.7%, FMR (Fidelity) 3.1%. Free-float effectively 85% with mix of passive, specialist biotech, and growth-fund holders.

Most interesting move: ARK Investment Management increased its position 28% in Q4/2025 — Cathie Wood's biotech specialist allocation. Baker Bros Advisors added 15% in Q1/2026 — sustained specialist accumulation despite the share-price rally from USD 12.15 trough. RA Capital opened a fresh 3.7% position in Q4/2025 at sub-USD 20 — the value-pivot from RA's typical early-stage focus. Notably, multiple long-duration specialist biotech funds (Avoro Capital, Foresite Capital) hold positions but have not actively traded — typical pattern of conviction-based muscle-disorder thesis investors.

Insider activity: CEO Kevin Koch (CEO since founding 2017) made no open-market purchases in 2024-2025 — standard restraint. CFO Brian Steed exercised options in Q4/2025 and held 80% of resulting shares. CMO Joel Hoover (joined 2023 from Pfizer) bought USD 220k in Q1/2026 — first major insider buy among the medical-clinical leadership. Director and co-founder Alan Russell has not transacted since 2022. The pattern of mid-management buying (CMO) is more credible than C-suite signaling because the medical leadership is closest to the Phase 2/Phase 3 data quality.

Short interest 13.3% (short ratio 10.3 days to cover) — moderate-elevated. The bear thesis is concentrated on (1) sevasemten Phase 3 GRAND-DM readout binary risk, (2) competition from Sarepta gene therapy in Duchenne (Elevidys), (3) Bristol-Myers Camzyos entrenchment in HCM, and (4) HFpEF program early-stage uncertainty.

P/E meaningless (no profits). P/S meaningless (no revenue). P/B 7.2x reflects pre-commercial biotech multiple. The right valuation framework is sum-of-parts NPV. Sevasemten Becker NPV (70% probability + 30% peak penetration of 15k Becker patients + USD 400k annual) approximately USD 1.5-2.0 bn. Sevasemten Duchenne NPV (50% probability + combination + 25% penetration) approximately USD 1.0-1.5 bn. EDG-7500 HCM NPV (45% probability + 25% market share + USD 250k annual) approximately USD 0.8-1.2 bn. EDG-15400 HFpEF NPV (30% probability + USD 50 bn addressable market) approximately USD 1.0-1.5 bn. Total NPV USD 4.3-6.2 bn versus current enterprise value approximately USD 3.2 bn (USD 3.6 bn market cap minus USD 0.4 bn cash). Sell-side PT consensus USD 43.67 (range USD 20-52): JP Morgan most bullish at USD 52 (Phase 3 success + HCM advances + HFpEF validates), HSBC most bearish at USD 20 (Phase 3 miss + cardiac portfolio early). 12 analysts cover, recommendation buy. Implied probability of pipeline-validation in current price approximately 50%. Bull case USD 55 (+66%) on Phase 3 GRAND-DM positive + HCM Phase 2 successful + HFpEF validates. Bear case USD 15 (-55%) on Phase 3 GRAND-DM miss + competitive intensification.

1. H2 2026: EDG-7500 HCM Phase 1 safety data + Phase 2 trial initiation
2. Q1 2027: EDG-15400 HFpEF Phase 1 first patient data — proof-of-concept for HFpEF mechanism
3. H2 2027: Sevasemten Phase 3 GRAND-DM Becker MD primary endpoint readout — largest single catalyst

Edgewise Therapeutics is a high-conviction muscle-disorder platform biotech with three programs in three distinct therapeutic areas (DMD/BMD, HCM, HFpEF) — meaningful diversification from single-asset biotech risk. The lead sevasemten program has positive Phase 2 data and Phase 3 already enrolling. The cardiac portfolio (EDG-7500 HCM, EDG-15400 HFpEF) provides optionality that is not yet priced into the share price. The 13.3% short interest combined with ARK and Baker Bros sustained accumulation is the classic specialist-conviction setup. I size EWTX at 0.75-1.5% as a high-conviction biotech-platform satellite. The trade I would not make is sizing above 2% — sevasemten Phase 3 GRAND-DM is a real binary in 2027 and the cardiac portfolio is still early-stage. Add trigger: any positive Phase 1 HCM data + sevasemten Phase 3 interim safety update. Cut trigger: any sevasemten Phase 3 interim safety signal or competitive announcement from Sarepta on Duchenne. This is a 12-24 month accumulation-and-catalyst trade — when sevasemten Phase 3 positive reads out in 2027, take meaningful profits because the cardiac portfolio still has multi-year clinical development ahead.